Compare · DRTS vs RMD
DRTS vs RMD
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.09B, about 26.5x DRTS ($1.25B).
- Over the past year, DRTS is up 229.3% and RMD is down 10.2% - DRTS leads by 239.5 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 1 for DRTS).
- RMD has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- ResMed Inc.
- Price
- $13.17-2.52%
- $242.35+2.97%
- Market cap
- $1.25B
- $33.09B
- 1M return
- -12.67%
- +6.16%
- 1Y return
- +229.25%
- -10.21%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 9
- Recent ratings
- 7
- 25
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DRTS
- Alpha Tau to Participate in October Investor Conferences
- Alpha Tau to Participate in September Investor Conferences
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- Chief Financial Officer Levy Raphi exercised 2,871 units of Ordinary Shares at a strike of $2.98 and sold $43,073 worth of Ordinary Shares (2,871 units at $15.00) (SEC Form 4)
- Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
- Chief Financial Officer Levy Raphi exercised 17,730 units of Ordinary Shares at a strike of $2.98 and sold $248,277 worth of Ordinary Shares (17,730 units at $14.00) (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target